Tranexamic Acid in Adolescents With Heavy Menstrual Bleeding

This is a multi-center (5 sites) open-label, single-arm, efficacy study of Lysteda in the treatment of adolescent females (10-19 years of age) with heavy menstrual bleeding (HMB). Each subject will receive oral Lysteda 1.3 grams three times daily during the first five days of menses. Subjects will be monitored over the course of four menstrual cycles (1 pre-treatment cycle and 3 treatment cycles). During all cycles, assessments of menstrual bleeding will be performed using the Menorrhagia Impact Questionnaire (MIQ) and Pictorial Blood Assessment Chart (PBAC).

The study will begin as a currently funded pilot study to assess the efficacy of Lysteda in 32 patients followed to study completion.

Inclusion criteria

• Menstruating females 10-19 years of age
• Non-smoker
• Physician and patient have agreed to initiate Lysteda
• Diagnosis of HMB based on the medical judgment of the principal or site investigator
• Subjects must report menstrual periods occurring within 21-60 days from the start of one period to the start of the next menstrual period
• Negative pregnancy test
• Informed consent obtained and signed
• Informed assent obtained and signed
• Understanding of study procedures
• Ability to comply with study procedures for the entire length of the study
• Subjects should be either sexually inactive (abstinent) or agree to use a barrier method with spermicide in the event of sexual activity throughout the study period

Exclusion criteria

• Active thromboembolic disease, history of thromboembolic disease (including retinal vein or artery occlusion), known inherited thrombophilia, or family history of thrombosis in a first degree relative
• Subject has a severe medical or psychiatric illness that, in the opinion of the Investigator, would affect subject safety or compliance
• Clinical evidence of severe bleeding disorder. Patients with mild bleeding disorders such as type 1 von Willebrand disease, mild platelet function defects such as platelet storage pool or release defects, and patients with bleeding due to Ehlers Danlos syndrome WILL be eligible to participate in the study.
• Pregnancy within the past 6 months and/or breast-feeding
• Use of hormonal contraception (estrogen and progestin) within 3 months of study entry, or anticipated need to initiate estrogen-containing hormonal contraception during the study period
• Use of systemic steroids within 1 month of study entry
• History of subarachnoid hemorrhage
• History of Hepatitis B, C, or HIV
• Baseline creatinine >20% above the upper limit of normal for age
• Severe anemia (hemoglobin <8 g/dL)
• Systolic blood pressure <85 or diastolic blood pressure <55
• Heart rate <50 at time of screening
• Use of intranasal DDAVP during menses will be permitted, but only if the patient has a history of using DDAVP consistently for ≥3 menstrual cycles prior to study enrollment, so that change in menstrual blood loss due to addition of Lysteda can be assessed. Use of one-time DDAVP during a DDAVP/Stimate challenge is also permitted during the study period, as is use of DDAVP in the event of severe epistaxis, trauma, or surgical procedures during the study period.